Quantinuum upsizes Nasdaq IPO to roughly $1.43B at up to $14.3B valuation in amended Form S-1
Per a Form S-1/A that Quantinuum Inc. filed with the SEC on 2026-06-01 (Registration No. 333-295701), the Honeywell-controlled trapped-ion company increased its proposed Nasdaq IPO to 26,500,000 shares (from 21,052,632) at a raised price range of $53.00-$55.00 per share (from $45.00-$50.00), implying gross proceeds of roughly $1.43B and a valuation of up to about $14.3B under the ticker QNT. According to Bloomberg, the upsize lifts the offering from a prior ceiling near $1.05B and a roughly $12.7B valuation set in the prior amendment dated 2026-05-26. The company is reported to price on 2026-06-03 and to begin trading on 2026-06-04, with J.P. Morgan and Morgan Stanley as lead book-running managers. This event was surfaced on 2026-06-02 after the scheduled 2026-06-01 run had completed.
Upsizing the year's largest pure-play quantum IPO by roughly 40% in proceeds with a raised price range is investor-material and consistent with the §8.2 score-7 'unexpected corporate action at a tracked public company' anchor; cross-verified against the SEC-filed S-1/A, the upsize is a concrete pre-pricing terms revision rather than a completed raise.
Pricing on 2026-06-03 will set the first public-market comparable for the trapped-ion modality and anchor Honeywell's deconsolidation economics; a top-of-range print would establish a roughly $14.3B reference valuation against which IonQ and Rigetti trade.